

Inside the Issue: The Emerging Role of Cereblon E3 Ligase Modulators in Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following features is associated with the primary mechanism of action of the pharmacologic class of CELMoDs (cereblon E3 ligase modulators)?
 - T-cell/NK-cell activation
 - Complement activation
 - Antibody-dependent cellular cytotoxicity
 - Ubiquitin-proteasome pathway
- Recently announced results of the Phase III EXCALIBER-RRMM trial evaluating iberdomide with daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for patients with relapsed/refractory (R/R) multiple myeloma (MM) included which efficacy finding?
 - A numerical but nonsignificant improvement in minimal residual disease (MRD) negativity rates with the iberdomide-containing regimen
 - A statistically significant improvement in MRD negativity rates with the iberdomide-containing regimen
 - A numerical but nonsignificant improvement in overall survival (OS) with the iberdomide-containing regimen
 - A statistically significant improvement in OS with the iberdomide-containing regimen
- Which of the following descriptions best represents the study design of the SUCCESOR-2 trial?
 - A Phase I/II study evaluating iberdomide/cyclophosphamide/dexamethasone for R/R MM
 - A Phase I/II study evaluating mezigdomide/daratumumab/bortezomib/dexamethasone for newly diagnosed MM
 - A Phase III study evaluating iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
 - A Phase III study evaluating mezigdomide/carfilzomib/dexamethasone versus pomalidomide/carfilzomib/dexamethasone for R/R MM
- Which of the following doses of iberdomide demonstrated the greatest response improvement over 24 cycles in the Phase II EMN26 study evaluating maintenance iberdomide after transplant for newly diagnosed MM?
 - 0.75 mg
 - 1.0 mg
 - 1.3 mg
- The Phase III DETERMINATION 2 study is evaluating which of the following induction regimens for transplant-eligible patients with newly diagnosed MM?
 - Iberdomide/bortezomib/dexamethasone
 - Daratumumab/iberdomide/dexamethasone
 - Isatuximab/iberdomide/dexamethasone
 - Daratumumab/iberdomide/bortezomib/dexamethasone
 - Isatuximab/iberdomide/bortezomib/dexamethasone